HbA1c, insulin use predict real-world response to GLP-1 receptor agonists in type 2 diabetes

A patient’s response to GLP-1 receptor agonist therapy in type 2 diabetes depends on several pretreatment characteristics, including baseline HbA1c, diabetes duration, age and use of insulin therapy, according to a real-world analysis published in Current Medical Research and Opinion.

Source: HbA1c, insulin use predict real-world response to GLP-1 receptor agonists in type 2 diabetes